Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the real world daily practice.

Detailed Description
-----------------
Consecutive patients receiving New DES without a mixture of other DES

Official Title
-----------------
Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Conditions
-----------------
Coronary Artery Disease, Percutaneous Transluminal Coronary Angioplasty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: coronary disease amenable to percutaneous coronary intervention (PCI) no clinical and lesion limitations Exclusion Criteria: patients with a mixture of several DES terminal illness with life expectancy less than 1 year patients with cardiogenic shock

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DESSIAN<br>consecutive patients receiving CYPHER stent | |
| K-XIENCE<br>consecutive patients receiving Xience stent | |
| GENOUS<br>consecutive patients receiving GENOUS stent | |
| ELEMENT<br>consecutive patients receiving PROMUS-ELEMENT stent | |
| PRIME<br>consecutive patients receiving XIENCE-PRIME stent | |
| NOBORI<br>consecutive patients receiving NOBORI stent | |
| INTEGRITY<br>consecutive patients receiving RESOLUTE-INTEGRITY stent | |
| XPEDITION<br>consecutive patients receiving XIENCE-XPEDITION stent | |
| BIOMATRIX<br>consecutive patients receiving BIOMATRIX stent | |
| CILOTAX<br>consecutive patients receiving CILOTAX stent | |
| DEB<br>consecutive patients receiving Drug eluting balloon | |
| DESYNE<br>consecutive patients receiving DESYNE stent | |
| PREMIER<br>consecutive patients receiving PROMUS-PREMIER stent | |
| ORSIRO<br>consecutive patients receiving ORSIRO stent | |
| ONYX<br>consecutive patients receiving ONYX stent | |
| BVS<br>consecutive patients receiving Bioresorbable Vascular Scaffold | |
| BVS AMI<br>consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold | |
| Ultimaster<br>consecutive patients receiving Ultimaster stent | |
| Synergy<br>consecutive patients receiving Synergy stent | |
| Biofreedom<br>consecutive patients receiving Biofreedom stent | |
| Firehawk<br>consecutive patients receiving Firehawk stent | |
| DESyne X2<br>consecutive patients receiving DESyne X2 stent | |
| Sierra<br>consecutive patients receiving Sierra stent | |
| Tansei<br>consecutive patients receiving Tansei stent | |
| Synergy XD and Synergy Megatron™<br>consecutive patients receiving Synergy XD or Synergy Megatron™ stent | |
| Xience-Skypoint<br>consecutive patients receiving Xience-Skypoint stent | |
| Coroflex ISAR NEO<br>consecutive patients receiving Coroflex ISAR NEO stent | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) |  | at 12 months post procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death (all-cause and cardiac) |  | at 12 months and annually up to 5 years | 
| Myocardial infarction |  | at 12 months and annually up to 5 years | 
| Stent thrombosis |  | at 12 months and annually up to 5 years | 
| Target-lesion and target-vessel revascularization |  | at 12 months and annually up to 5 years | 
| Stroke |  | at 12 months and annually up to 5 years | 
| Procedural success |  | at 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary disease, drug eluting stent